AI Consensus Investment Thesis
Abbott Laboratories (ABT) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY$115
+11.7%+13.2% incl. dividends5-Year
BUY$170
+65.7%+77.6% incl. dividendsLatest flagship insight
Medical Device Compounding Unlocks Durable Value Beneath Litigation and Leverage Overhangs
Independent analysis reveals high consensus that accelerating continuous glucose monitoring and transcatheter cardiovascular interventions drive durable organic compounding. While headline infant formula litigation and debt-funded oncology integration temporarily compress reported margins, robust free cash conversion insulates dividend growth and funds deleveraging against persistent macroeconomic discount-rate headwinds.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Superintelligence (Anthropologist), J.P. Morgan (Titan), Michael Burry (Vulture), Universal Investor (Polymath), Warren Buffett (Value Purist), Sherlock Holmes (Whistleblower), Machiavelli (Insider), Ray Dalio (Strategist), Elon Musk (Visionary). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Abbott Laboratories at the forecast anchor (2026-09-18): $17,759 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 1.4% net dividend yield for Abbott Laboratories.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 105.06 | +2.39% | +2.39% | Third-quarter results validate oncology diagnostics integration while infant formula settlement finalization bounds headline liabilities. Resilient FreeStyle Libre sensor volume growth offsets macro discount-rate pressures, prompting initial valuation multiple stabilization from deeply depressed sentiment levels. |
| Q1 2027 | 107.92 | +2.72% | +5.18% | Full-year 2026 reporting confirms operating cash generation approaching eight billion dollars, meeting guidance expectations. Management's 2027 outlook highlights steady continuous glucose monitoring adoption and initial oncology commercial cross-selling, reassuring institutional allocators regarding capital allocation discipline. |
| Q2 2027 | 111.68 | +3.48% | +8.84% | First anniversary of the oncology acquisition establishes clean comparable sales growth benchmarks. Accelerating TriClip procedural volumes and European pulsed-field ablation commercialization cushion against higher sovereign bond yields, sustaining steady operational earnings compounding across core divisions. |
| Q3 2027 | 114.58 | +2.60% | +11.66% | Mid-year consolidation reflects seasonal procedure moderation and persistent hospital procurement scrutiny. Stable recurring reagent testing on Alinity systems and expanding Libre Duo distribution prevent valuation slippage, anchoring equity performance during broader macroeconomic growth deceleration. |
| Q4 2027 | 118.62 | +3.53% | +15.61% | Announcement of the fifty-fifth consecutive annual dividend increase reinforces dividend aristocrat credibility. Cash generation funds visible acquisition debt retirement, reducing perceived balance-sheet leverage risk as favorable appellate rulings begin trimming residual infant formula litigation exposure. |
| Q1 2028 | 122.56 | +3.32% | +19.44% | Fiscal 2027 results showcase operating margins expanding toward nineteen percent as oncology purchase-accounting dilution begins to abate. Strong consumable sensor replenishment and steady emerging-market branded generic drug demand drive solid adjusted earnings per share progression. |
| Q2 2028 | 126.45 | +3.17% | +23.23% | Pulsed-field ablation systems capture domestic electrophysiology market share from legacy radiofrequency competitors. High attachment rates for cardiovascular consumables bolster device division gross margins, counteracting persistent international volume-based procurement pricing pressures across European and Asian hospitals. |
| Q3 2028 | 128.27 | +1.44% | +25.01% | Mid-year earnings demonstrate accelerating cash conversion as twelve-month free cash flow reaches nine billion dollars. Management continues prioritizing balance-sheet deleveraging over aggressive buybacks, building institutional confidence in structural solvency and earnings quality amidst tight monetary policy. |
| Q4 2028 | 132.58 | +3.36% | +29.21% | Formalization of additional infant formula settlement inventories clears headline legal uncertainty, unlocking modest multiple expansion. Consumer metabolic biowearable rollouts broaden non-diabetic recurring revenue streams, positioning the business for sustained mid-single-digit organic top-line compounding into year-end. |
| Q1 2029 | 135.49 | +2.20% | +32.05% | Full-year 2028 reporting confirms net leverage contracting below two times EBITDA. Restored balance-sheet flexibility allows leadership to reactivate selective share repurchases, supporting per-share intrinsic value growth as core laboratory diagnostic system placements sustain recurring reagent pull-through. |
| Q2 2029 | 139.38 | +2.87% | +35.84% | Next-generation continuous glucose-ketone dual sensors gain European commercial traction, defending market share against specialized medtech rivals. Favorable reimbursement coverage for intensive insulin cohorts expands addressable sensor volumes, driving mid-single-digit quarterly equity appreciation on high gross margins. |
| Q3 2029 | 142.65 | +2.34% | +39.02% | Late-summer healthcare utilization trends remain solid across North American hospital networks. While tariff frictions and foreign exchange translation create modest margin drag, Abbott's non-discretionary clinical portfolio delivers dependable defensive earnings stability relative to economically sensitive sectors. |
| Q4 2029 | 147.01 | +3.06% | +43.27% | Annual free cash flow surpasses ten billion dollars, funding accelerated open-market share retirements and another dividend increase. Tricuspid valve repair adoption expands across aging demographics, reinforcing structural heart leadership and elevating corporate operating margins toward twenty percent. |
| Q1 2030 | 150.70 | +2.51% | +46.87% | Fiscal 2029 financials confirm consistent seven percent organic revenue compounding across all four pillars. Oncology diagnostic screening achieves widespread routine outpatient adoption, validating multi-year merger synergies and prompting equity research analysts to lift long-term cash flow forecasts. |
| Q2 2030 | 153.59 | +1.92% | +49.69% | Global adoption of consumer metabolic wellness monitors scales manufacturing efficiencies, lowering unit sensor production costs. Automated sensor assembly lines protect consolidated gross margins against payer price resistance, ensuring dependable mid-single-digit operating income expansion across international commercial channels. |
| Q3 2030 | 155.90 | +1.50% | +51.93% | Late-cycle macroeconomic deceleration prompts broad institutional capital rotation toward defensive healthcare stalwarts. Abbott's low financial leverage, pristine credit rating, and non-cyclical chronic disease management portfolio command an enduring safe-haven bid across sovereign wealth and pension funds. |
| Q4 2030 | 159.70 | +2.44% | +55.64% | Management announces its fifty-eighth consecutive annual dividend hike alongside expanded share buybacks. Disciplined manufacturing execution across cardiovascular and diagnostic divisions shields profitability from raw-material inflation, securing dependable quarterly price performance into the close of the fiscal year. |
| Q1 2031 | 163.33 | +2.27% | +59.17% | Full-year 2030 results demonstrate normalized adjusted earnings per share crossing eight dollars on sustained operational discipline. The market fully prices Abbott's transformed oncology diagnostics and diabetes care platforms, completing multiple rerating toward historical peer averages as legal clouds evaporate. |
| Q2 2031 | 166.74 | +2.09% | +62.50% | Next-generation continuous molecular monitoring and leadless cardiac pacing pipelines achieve key clinical milestones, reinforcing pipeline visibility into the mid-2030s. Strong cash conversion funds ongoing internal innovation while supporting consistent capital returns to long-term shareholders. |
| Q3 2031 | 169.99 | +1.95% | +65.67% | The five-year forecast culminates with Abbott firmly established as a premier diversified medtech and diagnostics compounder. Normalized earnings power, extinguished litigation overhangs, and successful post-merger integration deliver resilient total shareholder returns across shifting macroeconomic and interest-rate regimes. |
A pronounced optical disconnect masks underlying operational resilience. While headline earnings are depressed by purchase-accounting amortization from the recent multi-billion-dollar oncology acquisition and ongoing legal provisions, core organic revenue is compounding steadily. Dominant market positions in continuous glucose monitoring and transcatheter cardiovascular interventions generate dependable, high-margin consumable streams that insulate operating cash flows. The primary valuation tension centers on elevated post-acquisition leverage and headline tort risks against an unappreciated recurring cash flow yield. As integration expenses lap and master settlements ring-fence legacy liabilities, operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry will drive normalized multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry across the multi-year investment horizon.
Key insights
- Consumable sensor replenishment and structural heart procedure volumes provide recurring annuity revenues that decouple enterprise operating cash flows from cyclical hospital equipment spending.
- Substantial post-transaction balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry debt prioritizes early operational cash flow toward deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry, subordinating discretionary share repurchases until gross leverage ratios normalize below target.
- Structured legal settlements transform existential mass-tort tail risks into ring-fenced, predictable corporate liabilities that are comfortably absorbable through ongoing organic free cash generation.
Abbott Laboratories looks cheaper than usual because headline accounting charges from a major cancer-testing acquisition and baby formula lawsuits have temporarily lowered reported profits. Beneath these one-time expenses, the core business is performing strongly. Millions of patients rely daily on continuous glucose monitors and life-saving heart devices, generating dependable recurring cash flows that protect the company's dividend and fund steady debt repayment.
Key insights
- Essential medical devices generate continuous recurring customer sales that remain completely protected from wider economic downturns.
- Cash flow is directed toward paying down acquisition borrowing before management expands large share repurchase programs.
- Recent legal settlements cap major lawsuit uncertainties, turning open-ended risks into manageable, easily funded corporate payments.
Deep Dive
Market consensus currently discounts the company as an encumbered, sluggish healthcare conglomerate trapped between unresolved infant formula mass-tort liabilities, post-pandemic diagnostic volume erosion, and balance-sheet indigestion following its multi-billion-dollar oncology acquisition. Investors fixate on backward-looking GAAP earnings volatility and higher benchmark interest rates, assuming regulatory scrutiny and elevated leverage permanently cap valuation multiples and restrict near-term total returns.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Market consensus currently discounts the company as an encumbered, sluggish healthcare conglomerate trapped between unresolved infant formula mass-tort liabilities, post-pandemic diagnostic volume erosion, and balance-sheet indigestion following its multi-billion-dollar oncology acquisition. Investors fixate on backward-looking GAAP earnings volatility and higher benchmark interest rates, assuming regulatory scrutiny and elevated leverage permanently cap valuation multiples and restrict near-term total returns.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially underestimates value through underpricing caused by confusing transitory accounting charges with structural business impairment. Trailing reported GAAP earnings reflect non-cash acquisition amortization and non-operating legal reserves, masking underlying operational resilience evidenced by nearly eight billion dollars in normalized free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. Investors overlook that double-digit expansion in continuous glucose monitoring and transcatheter cardiovascular interventions delivers high-margin recurring cash flows. While debt reduction will constrain immediate share repurchases, the resulting cash conversion justifies a meaningful valuation reratingvaluation reratingA change in the valuation multiple assigned to a business or asset after expectations about growth, quality, or risk change.View full glossary entry.
Repricing Catalyst
What could make the market recognize and close that gap? Convergence will be triggered by sequential quarterly earnings reports demonstrating oncology diagnostics margin accretion and double-digit medical device revenue expansion, alongside formal judicial execution of infant formula settlement frameworks through late 2026 and 2027. Demonstrating clean organic comparable sales growth approaching seven percent while visibly reducing net debtnet debtTotal debt minus cash and cash equivalents.View full glossary entry will prove that acquisition leverage and legal overhangs are contained, prompting institutional allocators to reprice shares toward historical medtech valuation benchmarks.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Stabilization
Sentiment centers on stabilization amidst persistent litigation fear and rate-driven multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. Disagreement focuses on whether the multi-billion-dollar oncology acquisition represents dilutive debt leverage or a transformative high-margin screening monopoly, determining whether forward multiplesforward multipleForward multiple is a valuation ratio based on forecast earnings, sales, or cash flow rather than historical results.View full glossary entry expand steadily or remain permanently constrained.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic setup presents a mixed backdrop for enterprise valuation. Restrictive monetary policy and elevated sovereign bond yields enforce higher hurdle discount rates across large-cap healthcare assets. However, non-discretionary clinical demand, recurring medical consumable utilization, and robust organic cash generation provide exceptional defensive resilience, turning late-cycle economic deceleration into a relative operational and balance-sheet advantage.
Advisor Disagreement
What do our AI Advisors disagree about most? The central debate across reports centers on whether Abbott's multi-billion-dollar oncology acquisition enhances long-term compounding or introduces dangerous debt overhang into an elevated interest-rate regime. Bullish analyses argue that Cologuard's established clinical guideline positioning and FreeStyle Libre's consumable expansion will rapidly de-lever the balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry while driving operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward twenty percent. Conversely, skeptical viewpoints contend that twenty billion dollars in new debt and persistent infant formula litigation tail risks will constrain capital flexibility and freeze multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. Observable net debtnet debtTotal debt minus cash and cash equivalents.View full glossary entry reduction and comparable diagnostics growth across 2027 earnings reports will definitively resolve this debate.
Base-Case Forces
Event Risk ScoreVery Low5/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Continuous Glucose Monitoring Secular Scaling | Innovation And Product | +24% | +25% | Expanding beyond intensive diabetes care into basal and pre-diabetic populations drives recurring sensor replenishment, making patient utilization an annuity-like revenue stream. Supported by automated manufacturing and over-the-counter wellness platforms, this high-margin consumable ecosystem insulates operating profits from broader economic downturns, sustaining high-single-digit organic growthorganic growthThe rate at which a company expands revenue through internal operations rather than acquisitions.View full glossary entry and expanding consolidated corporate gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry. |
| Structural Heart and Electrophysiology Expansion | Competitive Positioning | +18% | +19% | Proprietary transcatheter tricuspid and mitral valve repair platforms alongside pulsed-field ablation catheter rollouts command formidable clinical and regulatory switching barriers. High-acuity surgical volumes remain thoroughly insulated from macroeconomic fluctuations, enabling Abbott to capture premium hospital reimbursement. This procedural acceleration expands medical device operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry, converting volume gains into durable, multi-year operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry growth. |
| Oncology Diagnostic Screening Synergies | Capital Allocation | +16% | +16% | Integrating established non-invasive colorectal cancer screening assets into Abbott's ubiquitous global hospital and laboratory distribution channels unlocks substantial commercial scale. As initial acquisition-related financing dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry and purchase-accounting amortizations lap through 2027, cross-selling across primary-care networks accelerates recurring testing volumes, delivering high-margin operational leverage that directly enhances diagnostic segment earnings. |
| Emerging Market Branded Generics Compounding | Operational Efficiency | +11% | +13% | The Established Pharmaceuticals business leverages deeply entrenched local distribution networks across demographic growth corridors in Latin America and Asia, selling trusted off-patent medicines directly into cash-pay markets. Bypassing Western reimbursement price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry and patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry vulnerabilities, this localized operational engine generates reliable high-single-digit volume compounding and defensive, countercyclical free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Acquisition Debt Servicing and DeleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry | Capital Allocation | -10% | -10% | Financing the twenty-one-billion-dollar oncology transaction elevated gross debt obligations past thirty-two billion dollars under a restrictive monetary backdrop. Heightened annual interest expense and priority debt paydown temporarily divert operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry away from discretionary share repurchases. Until gross leverage normalizes toward historical levels, elevated capital absorption constrains per-share earnings growth and caps multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
| Preterm Infant Formula Residual Litigation | Regulatory | -9.0% | -8.0% | Although landmark master settlements bound approximately two thousand state claims, thousands of residual infant formula lawsuits remain pending in federal and state courts. Ongoing defense expenditures, compliance oversight, and the persistent potential for adverse trial verdicts impose a lingering sentiment overhang, requiring conservative balance-sheet contingency reserves that depress headline reported net earnings. |
| Restrictive Cost of Capitalcost of capitalCost of capital is the required return investors demand to fund a business, project, or asset, reflecting risk and financing mix.View full glossary entry Regime | Macroeconomic And Macrofinancial | -8.0% | -4.0% | Persistent benchmark sovereign yields hovering near five percent enforce higher hurdle discount rates across mega-cap defensive healthcare equities. Tight monetary policy raises debt refinancingdebt refinancingReplacing existing debt with new borrowing, often to change maturity, interest cost, currency, or covenants.View full glossary entry costs and strains non-profit hospital capital budgets, lengthening equipment replacement cycles for automated diagnostic instrumentation and compressing price-to-earnings multiples across diversified medtech peers. |
| Reimbursement Austerity and Pricing Resistance | Competitive Positioning | -7.0% | -8.0% | Intensifying price competition in continuous glucose monitoring alongside international volume-based procurement mandates in China and Europe restricts realized unit prices. Payer bargaining and mandatory tender discounts prevent procedural volume gains from flowing fully into operating profits, diluting incremental gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry across mature diagnostics, nutrition, and cardiovascular product lines. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Uncontained Multidistrict Tort Settlement Contagion | 24% | -26% | State appellate courts invalidate master settlement frameworks while adverse bellwether trials assess multi-billion-dollar punitive damages across unreserved infant formula claims through 2028. The resulting liability pool exceeding five billion dollars would deplete corporate cash, halt share repurchases, threaten credit metrics, and force substantial debt issuance during an elevated rate environment, causing severe institutional equity liquidation. |
| Severe Biosensor Quality and Recall Shock | 18% | -24% | A catastrophic manufacturing defect or FDA distribution restriction compromises flagship continuous glucose monitor production by late 2027, triggering a mandatory global Class I recall. Extended supply suspensions and reputational impairment would force patients toward competing platforms, erasing billions in high-margin consumable sensor sales and permanently depressing Abbott's primary organic growthorganic growthThe rate at which a company expands revenue through internal operations rather than acquisitions.View full glossary entry engine and enterprise valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Universal Continuous Glucose Monitoring Reimbursement | 35% | +23% | Centers for Medicare & Medicaid Services and commercial insurers formally expand coverage mandates to include all thirty million non-insulin Type 2 diabetes patients by 2028. Driven by real-world clinical outcomes proving cardiovascular event reductions, FreeStyle Libre addressable domestic volume would triple, injecting over two billion dollars in high-margin recurring operating income and sparking an aggressive institutional multiple rerating. |
| Comprehensive Legal Preemption Verdict Resolution | 32% | +19% | Federal appellate courts or statutory reform establish definitive federal preemption across all pending state-level preterm infant formula claims, citing FDA-mandated nutritional standards. Enacted by late 2027, this judicial breakthrough extinguishes residual mass-tort liabilities overnight without additional multibillion-dollar cash reserves, immediately releasing trapped balance-sheet liquidity and triggering a rapid valuation multiple expansionvaluation multiple expansionAn increase in valuation ratios such as P/E or EV/EBITDA, often driven by stronger growth or lower perceived risk.View full glossary entry toward historic medtech leader premiums. |
Company Financial Analysis
Abbott Laboratories Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Abbott's recent financial headlines look deceptive at first glance. Reported accounting profit fell sharply in mid-2026, but this drop was caused by non-operating legal settlement reserves and purchase-accounting charges from acquiring Exact Sciences rather than slowing customer sales. In fact, underlying business revenue climbed to forty-six point six billion dollars over the trailing twelve months, powered by resilient high-single-digit growth across medical devices and branded generic medicines. The true operational health appears in cash generation. Abbott produced nearly eight billion dollars in trailing free cash flow, showing that its core commercial engine remains exceptionally profitable. As acquisition integration charges fade, headline earnings will re-align with cash flows, supporting steady long-term compounding.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 44.3B | USD 6.5B | USD 7.4B |
| 2024 | USD 42B | USD 13.4B | USD 6.4B |
| 2023 | USD 40.1B | USD 5.7B | USD 5.1B |
| 2022 | USD 43.7B | USD 6.9B | USD 7.8B |
| 2021 | USD 43.1B | USD 7.1B | USD 8.6B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 33.6x | TTM | Native | USD / USD |
| 2024 | 14.7x | TTM | Native | USD / USD |
| 2023 | 33.6x | TTM | Native | USD / USD |
| 2022 | 27.8x | Annual | Native | USD / USD |
| 2021 | 35.5x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Abbott's profitability reveals an underlying improvement in product quality. Adjusted gross margins widened toward fifty-eight percent in mid-2026, driven by a favorable mix shift toward high-margin medical devices, glucose sensors, and precision oncology screening. These proprietary medical products carry strong pricing power, effectively counteracting raw-material inflation, hospital budget constraints, and international tariff headwinds. Although reported net income margins dipped temporarily due to acquisition financing and legal accruals, operating margins are positioned to recover toward twenty percent. As one-off merger expenses subside and automated manufacturing lowers unit sensor costs, operational leverage will drive accelerated profit growth across the five-year investment horizon.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 8B | 18.2% | 14.7% |
| 2024 | USD 6.8B | 16.3% | 31.9% |
| 2023 | USD 6.4B | 16.0% | 14.3% |
| 2022 | USD 8.4B | 19.2% | 15.9% |
| 2021 | USD 9.2B | 21.4% | 16.4% |
Balance sheet and leverage
AI Review
Abbott's balance sheet underwent a major shift in 2026 following the Exact Sciences acquisition, which was funded through a twenty-billion-dollar debt offering. Consequently, gross debt expanded to approximately thirty-two point six billion dollars by mid-year. While headline leverage ratios increased, the company's financial foundation remains solid, supported by fifty-two billion dollars in shareholder equity and strong operating liquidity. The critical priority for cash flow over the next two years is debt reduction rather than aggressive stock buybacks. Because annual free cash flow approaches eight billion dollars, Abbott can comfortably service its debt obligations, fund ongoing legal settlements, and protect its fifty-four-year dividend growth streak.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 15.1B | USD 8.9B | USD 6.5B net debt | 1.58x |
| 2024 | USD 15.3B | USD 8B | USD 7.7B net debt | 1.67x |
| 2023 | USD 15.9B | USD 7.3B | USD 9B net debt | 1.64x |
| 2022 | USD 17.9B | USD 10.2B | USD 8.1B net debt | 1.63x |
| 2021 | USD 19.3B | USD 10.2B | USD 9.5B net debt | 1.85x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has demonstrated careful capital discipline in its physical facilities. Annual capital expenditures have consistently averaged approximately five percent of revenue, totaling just over two billion dollars. Reinvestment focuses strictly on high-return manufacturing automation for continuous glucose monitors and cleanrooms for structural heart devices, avoiding wasteful factory overbuilding. The company's major strategic bet was inorganic: spending twenty-one billion dollars in March 2026 to acquire Exact Sciences. This transformative cancer-screening investment commits substantial capital, but relies on existing hospital distribution rather than heavy ongoing factory expansion. This targeted capital posture preserves strong cash conversion while building intellectual property moats.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 2.2B | USD 3B |
| 2024 | USD 2.2B | USD 2.8B |
| 2023 | USD 2.2B | USD 2.7B |
| 2022 | USD 1.8B | USD 2.9B |
| 2021 | USD 1.9B | USD 2.7B |
Quarterly Forecast Scenarios
Abbott Laboratories Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $99.53 | $105.40 | $108.77 | $750.26 | |
| $97.54 | $108.35 | $114.20 | $736.44 | |
| $98.52 | $111.95 | $118.77 | $743.40 | |
| $96.55 | $114.88 | $124.71 | $755.15 | |
| $98.48 | $118.93 | $129.70 | $776.22 | |
| $99.46 | $122.99 | $136.19 | $787.13 | |
| $101.45 | $126.88 | $141.63 | $802.83 | |
| $100.44 | $129.07 | $145.88 | $812.05 | |
| $102.45 | $133.35 | $151.72 | $839.18 | |
| $103.47 | $137.01 | $159.30 | $850.50 | |
| $103.47 | $140.88 | $162.49 | $872.39 | |
| $104.50 | $144.19 | $168.99 | $885.51 | |
| $106.59 | $148.65 | $174.06 | $909.56 | |
| $105.53 | $152.65 | $181.02 | $916.13 | |
| $107.64 | $156.11 | $186.45 | $936.51 | |
| $107.64 | $158.90 | $192.04 | $947.34 | |
| $109.79 | $162.81 | $197.81 | $969.59 | |
| $110.89 | $166.75 | $201.76 | $979.99 | |
| $109.78 | $170.09 | $205.80 | $999.60 | |
| $110.88 | $173.62 | $209.91 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The common pattern across reports identifies Abbott as an entrenched healthcare compounder whose core operational power is obscured by transient infant formula litigation and debt from the March 2026 oncology acquisition. However, significant divergence emerges in balance-sheet modeling: several reports rely on stale year-end 2025 leverage metrics, failing to reflect the twenty-billion-dollar debt issuance disclosed in the June 2026 Form 10-Q. Highest weight is allocated to independent analyses that rigorously incorporate verified SEC filings, reconciling acquisition dilution, realistic post-deal net debt of twenty-seven billion dollars, and residual mass-tort exposure covering thousands of infants. Reports that omit the transaction entirely or extrapolate multiple reratings without modeling debt service receive lower allocations. The credible contrarian case highlighting discount-rate gravity under persistent benchmark yields is preserved to restrain aggressive valuation assumptions. Unresolved litigation appellate timelines and continuous sensor pricing competition ultimately govern relative weighting.
Universal Investor AI
The Polymath
GPT-6 AstraExhibits superior research quality, citing verified SEC filings, June 2026 balance-sheet data showing thirty-two billion dollars in gross debt, FDA clearances, and oncology screening guidelines. Models realistic quarterly drawdowns and cautious deleveraging constraints. Assigned the highest weight of 0.15 for unmatched empirical rigor.
Universal Investor AI
The Polymath
Opus 5Provides exceptional empirical analysis of Q2 2026 results, distinguishing reported from comparable growth and detailing Exact Sciences financing notes. Accurately scopes the residual twelve-thousand-infant litigation docket and decelerating sensor growth. Assigned a substantial 0.14 weight for rigorous financial forensics and realistic path constraints.
Michael Burry AI
The Vulture
Gemini 3.8 FlashOffers sharp forensic analysis of infant formula litigation, accurately identifying the August and September 2026 settlements as ring-fencing events. Incorporates Exact Sciences screening synergies and realistic free cash flow yields. Assigned a 0.09 weight for rigorous legal risk bounding and sound cash conversion metrics.
Universal Investor AI
The Polymath
Gemini 3.8 FlashSynthesizes Exact Sciences integration, Libre Duo rollouts, and infant formula legal progress into a balanced seven-percent organic compounding scenario. Correctly captures integration friction while modeling realistic operating margin progression toward twenty percent. Assigned an 0.08 weight for thorough multi-factor integration and causal consistency.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashDemonstrates strong forensic grounding, evaluating the 670-million-dollar infant formula settlement alongside DOJ resolutions and post-acquisition amortization. Correctly highlights refinancing hurdles under tight monetary policy and Volt PFA rollout traction. Assigned an 0.08 weight for detailed legal and operational reconciliation.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashProvides a coherent macro-defensive compounding framework, highlighting FreeStyle Libre scaling and Exact Sciences oncology synergies. However, it relies on older pre-acquisition leverage figures and underestimates the initial debt service drag. Assigned a 0.07 weight reflecting solid operational insight tempered by loose balance-sheet assumptions.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashConstructs a detailed institutional thesis highlighting cardiovascular device leadership and oncology screening integration. However, its forecasted multiple expansion to twenty-four times forward earnings in an elevated rate regime is overly aggressive. Assigned a 0.07 weight for strong operational analysis tempered by optimistic valuation assumptions.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashEffectively combines Exact Sciences integration, electrophysiology adoption, and litigation de-risking within an owner-earnings framework. Models steady operating margin expansion toward twenty percent while acknowledging tariff and pricing frictions, justifying a 0.06 weight for solid causal consistency and realistic compounding.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashContributes distinctive insights into government WIC infant formula procurement hegemony and legal settlements, but omits the oncology acquisition and its debt burden. Assigned a 0.05 weight; its unique institutional analysis is valuable but bounded by capital structure blind spots.
Elon Musk AI
The Visionary
Gemini 3.8 FlashSupplies a valuable contrarian reality check on discount-rate gravity, tech disruption risks, and multiple compression under five-percent Treasury yields. However, it relies on optical trailing P/E distortions and omits the Exact acquisition, receiving a 0.05 weight for useful risk calibration.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashPresents strong biological demand framing for diabetes care and structural heart therapies. However, it completely omits the twenty-one-billion-dollar Exact Sciences acquisition and subsequent twenty-billion-dollar debt issuance, using outdated balance-sheet leverage metrics. Assigned a reduced 0.04 weight due to this major material omission.
Universal Investor AI
The Polymath
Gemini 3.8 FlashAccurately assesses core medical device momentum and Q2 2026 revenue trends, but fails to account for the Exact Sciences merger and its debt financing. Models a more conservative path that correctly captures litigation uncertainty, earning a 0.04 weight due to stale capital structure inputs.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashArticulates a classic economic moat thesis around FreeStyle Libre and structural heart implants, but completely ignores the March 2026 Exact Sciences acquisition and twenty-billion-dollar debt issuance. Stale balance-sheet inputs limit its forward utility, justifying a reduced 0.04 weight despite sound qualitative moat reasoning.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashDevelops an insightful human-telemetry narrative around FreeStyle Libre and structural heart repair, but completely overlooks the twenty-one-billion-dollar Exact Sciences transaction. Its reliance on pre-acquisition debt metrics and aggressive valuation targets requires downweighting to 0.04 due to incomplete material information.
Research Provenance
References & Context
This Abbott Laboratories consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 126 deduplicated sources retained for this batch.
- 01Device Classification Under Section 513(f)(2)(De Novo)accessdata.fda.gov
- 02Article - Glucose Monitor - Policy Article (A52464)cms.gov
- 03Abbott Diabetes Care, Inc. - 722046 - 01/23/2026 | FDAfda.gov
- 04Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 05ABBOTT LABORATORIES - Form 8-K - FY2026sec.gov
- 06abt-20251231sec.gov
- 07abt-20260630sec.gov
- 08www.sec.govsec.gov
- 09www.sec.govsec.gov
- 10Abbott Price Prediction: Where Will the Stock Be in 2027 - 24/7 Wall St.247wallst.com
- 11Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy - 24/7 Wall St.247wallst.com
- 12Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love - 24/7 Wall St.247wallst.com
- 13Abbott acquisition of Exact Sciences set to close on March 23, 2026 - Mar 20, 2026abbott.mediaroom.com
- 14Abbott completes acquisition of Exact Sciences - Mar 23, 2026abbott.mediaroom.com
- 15Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance - Jul 16, 2026abbott.mediaroom.com
And 111 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.